Protea Biosciences has teamed up with Agilent Technologies to offer drugmakers mass spectrometry alternatives to UV detection in QA/QC of recombinant proteins.
Contract research organization Charles River Laboratories has extended its initial three-year strategic partnership with AstraZeneca for an additional five years.
Malvern Instruments will buy GE Healthcare’s MicroCal business in a deal that adds protein analysis and formulation development tech to its expanding drug industry offering.
US CRO and discovery technology supplier XenoTech has launched CryostaX, which it claims is the largest single-freeze pool of human hepatocytes available to drug developers.
Preclinical drug testing specialist Absorption Systems has branched out and opened a new surgical lab designed to help pharmaceutical firms assess the safety of biomaterials and medical devices.
A new bioinformatics technique, developed by researchers at the US
Argonne National Laboratory, is allowing researchers to rapidly
screen the genetic sequences present microbial communities.
US researchers have developed a new biochip technology that could
dramatically reduce the need for animal testing during drug
development safety studies.
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
New research has shown that even if laboratory rats are genetically
identical they can still develop distinct metabolic profiles that
could skew drug toxicity and metabolism studies.
Finnish CRO Technical Research Center (VTT) has spun-off Zora
Biosciences, which becomes the only company in the Nordic region to
provide metabolomics services to pharma companies - a market with
high potential.
French bioprocess specialist LibraGen has released its first family
of active molecules produced using the firm's biocatalysis
technology onto the market.
The new Metabolomics system from ESA promises to speed up biomarker
discovery and reduce the overwhelming amounts of data often
associated with these studies.
Surface Logix has presented encouraging Phase 1 trial data for a
drug candidate that is being developed for the treatment of
abnormal levels of lipids in the bloodstream - a condition that
affects approximately 10 per cent of the...
A key study performed by US scientists has uncovered detailed
structural changes, which a catalytic enzyme undergoes in order to
carry out its biological function. The findings challenge
traditional hypothesis and may aid in future...
Applied Biosystems (AB) has given drug researchers a new software
application in thier quest to more quickly and accurately screen
drug candidates, which can be further developed into promising new
treatments.
BioTrove and Blue Sky Biotech announce a collaborative effort to
provide a unique service solution, utilising mass
spectrometry-based high-throughput screening assays on previously
unscreenable drug targets.
A new robotic system, which provides data for genetic engineering,
provides an additional method in rapid mass screening to identify
new species as pharma becomes more open to using microorganisms as
living factories for producing...
A toxicology-on-a-chip tool, which can analyse drug candidates for
toxicity before they advance to pre-clinical stages, has taken one
step further towards commercialisation as the technology promises
to aid laboratory researchers...
The world's largest drug company, Pfizer, is to make use of a gene
expression system developed at Dowpharma for the production of one
of its therapeutic proteins.
Contract service provider, GeneLogic, has formed a partnership with
Millenium Pharmaceuticals acquiring a technology program and an
associated research team as part of the deal. Millenium becomes the
first customer for this new service...
Researchers in Finland and Belgium have developed a new way of
making plant-derived compounds in cell cultures that should cut the
cost of manufacturing a raft of pharmaceuticals, including drugs
for cancer.
Scientists have started to develop what could be a biosynthetic
route to producing compounds that serve as precursors to a range of
industrial chemicals, including pharmaceuticals.
Two $500m-plus licensing deals reveal the rewards available to
biotech firms with novel drugs, but also the lengths large
biopharma companies will now go to secure exclusive rights to
promising candidates, even if they are in the...
NiKem Research says it has developed its ADMET capabilities to such
an extent that it can offer them as a service to customers involved
in drug discovery.
Switzerland's Tecan has introduced a range of laboratory automation
workstations, under the Freedom EVO banner, which are designed to
provide fluid handling applications in genomics, proteomics, drug
discovery and clinical diagnostics.
METabolic EXplorer, a French biotechnology company specialising in
the development and production of new biological processes for the
manufacturing of chemicals and pharmaceuticals, has bolstered its
scientific team with the appointment...
